Mega Lifesciences Public Company Limited

Report azionario SET:MEGA

Capitalizzazione di mercato: ฿32.9b

Mega Lifesciences Gestione

Criteri Gestione verificati 2/4

Mega Lifesciences Il CEO è Vivek Dhawan, nominato in Jan1988, ha un mandato di 38.5 anni. possiede direttamente 6.66% delle azioni della società, per un valore di THB 2.21B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 28.5 anni e 13.4 anni.

Informazioni chiave

Vivek Dhawan

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEO38.5yrs
Proprietà del CEO6.7%
Durata media del management28.5yrs
Durata media del Consiglio di amministrazione13.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Aggiornamento narrativa • Jun 24

MEGA: Higher Margins And Lower Growth Will Likely Keep Shares Fairly Valued

Analysts have kept their fair value estimate for Mega Lifesciences steady at THB35.0, explaining that slightly softer revenue growth assumptions are offset by a higher profit margin outlook and a marginally lower future P/E multiple in their updated price target work. What’s in the News for Mega Lifesciences No recent company specific news items for Mega Lifesciences were identified in the provided sources.
Aggiornamento narrativa • Jun 07

MEGA: Stable Assumptions And Margin Outlook Will Drive Future Upside

Analysts have kept their price target for Mega Lifesciences unchanged at THB 41.14, citing only small adjustments to projected revenue growth, profit margins and future P/E assumptions that do not materially alter their overall view of the stock. What's in the News No recent company specific news for Mega Lifesciences has been provided in the available sources.
Aggiornamento narrativa • May 24

MEGA: Higher Margin Outlook And Dividend Decision Will Support Future Upside

Analysts have trimmed their price target for Mega Lifesciences slightly to THB 41.14 from THB 41.17, reflecting updated assumptions that now pair a lower revenue growth outlook of 4.12% with a higher projected profit margin of 16.40% and a modestly lower future P/E of 16.67x. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).
Aggiornamento narrativa • May 06

MEGA: Stable Outlook And Upcoming Dividend Decision Will Drive Further Upside

Analysts have kept their fair value estimate for Mega Lifesciences steady at THB41.17 per share, with only minimal model tweaks related to the discount rate, profit margin outlook and future P/E assumptions. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).
Aggiornamento narrativa • Apr 21

MEGA: Higher Growth And Lower Margins Will Likely Keep Shares Fairly Valued

Analysts have lifted their price target on Mega Lifesciences from THB 32 to THB 35, citing updated assumptions around higher revenue growth, a slightly lower discount rate and a revised future P/E multiple, partially offset by a more conservative profit margin outlook. What's in the News Board meeting scheduled for Feb 24, 2026, to consider a dividend payment proposal for the year ended Dec 31, 2025 (company filing).
Aggiornamento narrativa • Apr 06

MEGA: Stable Outlook And Upcoming Dividend Decision Will Support Upside

Analysts have maintained their price target for Mega Lifesciences at THB41.17, citing unchanged assumptions regarding fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).
Aggiornamento narrativa • Mar 23

MEGA: Higher Fair Value And Upcoming Dividend Decision Will Support Upside

Analysts have lifted their fair value estimate for Mega Lifesciences from THB 38.21 to THB 41.17, citing updated assumptions for long term profit margins and a higher future P/E multiple. What's in the News A board meeting is scheduled for February 24, 2026 for Mega Lifesciences Public Company Limited.
Aggiornamento narrativa • Mar 09

MEGA: Higher Future P/E Will Support Upgraded Fair Value Outlook

Analysts have lifted their price target for Mega Lifesciences from THB 41.60 to THB 45.00. They highlighted updated assumptions that include slightly lower revenue growth and profit margins, together with a higher future P/E multiple.
Aggiornamento narrativa • Feb 23

MEGA: Updated Discount Rate And Margins Will Support Fair Pricing Ahead

Analysts have raised their price target on Mega Lifesciences to THB 38.21 from THB 34.58, citing updated assumptions related to slightly lower discount rates, adjusted revenue growth, modestly different profit margins and a revised future P/E multiple. Valuation Changes Fair Value: THB 34.58 to THB 38.21, indicating a modest uplift in the assessed share valuation.
Aggiornamento narrativa • Feb 09

MEGA: Fair Outlook Will Balance Softer Margins With Stronger Revenue Expectations

Narrative update on Mega Lifesciences The analyst price target for Mega Lifesciences has been lifted from ฿39.00 to ฿41.60, with analysts linking this change to updated assumptions for slightly lower discount rates, higher forecast revenue growth, a modestly softer profit margin, and a higher future P/E multiple. Valuation Changes Fair Value Estimate: Raised from THB 39.00 to THB 41.60, a small uplift in the assessed equity value.
Aggiornamento narrativa • Jan 25

MEGA: Stable Assumptions And Margins Will Support Fair Pricing Ahead

The analyst price target for Mega Lifesciences remains unchanged at ฿34.58, with analysts citing consistent assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. Valuation Changes Fair value: Unchanged at THB34.58 per share, with no adjustment to the underlying assumptions.
Aggiornamento narrativa • Jan 10

MEGA: Higher Margin Assumptions Will Likely Leave Shares Overvalued

The analyst fair value estimate for Mega Lifesciences has been adjusted from ฿26.00 to ฿32.00, with analysts pointing to updated assumptions around revenue growth, profit margins and forward P/E to support the higher target. Valuation Changes The fair value estimate has risen from THB 26.00 to THB 32.00 per share, reflecting updated assumptions in the model.
Aggiornamento narrativa • Dec 24

MEGA: Stable Margins And Earnings Outlook Will Support Fair Pricing Ahead

Analysts have reaffirmed their price target on Mega Lifesciences at THB 34.58 per share, citing unchanged assumptions for discount rate, revenue growth, profit margins, and future valuation multiples, which together support a steady outlook for the company’s fair value. Valuation Changes Fair Value: Unchanged at approximately THB 34.58 per share, indicating no revision to the overall equity valuation.
Aggiornamento narrativa • Dec 09

MEGA: Stable Margins And Earnings Outlook Will Support Fair Pricing Ahead

Analysts have maintained their price target on Mega Lifesciences at THB 34.58 per share, reflecting steady assumptions on revenue growth, profit margins, and valuation multiples despite the latest review of fundamentals. Valuation Changes Fair Value: Unchanged at approximately THB 34.58 per share, indicating no revision to the core valuation thesis.
Aggiornamento narrativa • Nov 25

MEGA: Improved Profit Margins And Revenue Estimates Suggest Fair Valuation Ahead

Analysts have raised their price target for Mega Lifesciences from THB 32.14 to THB 34.58. This reflects improved revenue growth forecasts and a slightly stronger profit margin outlook.
User avatar
Nuova narrativa • Jun 01

Expansion In Indonesia And Vietnam Will Fuel Emerging Wellness Markets

Strategic expansion in high-growth markets and local manufacturing reduce operational risks and support sustainable revenue and margin growth.

AMMINISTRATORE DELEGATO

Vivek Dhawan (65 yo)

38.5yrs
Mandato

Mr. Vivek Dhawan is CEO & Executive Director of Mega Lifesciences Public Company Limited from 2013 and serves as its Head of ESG & Chief Coach. He joined the Mega Lifesciences Public Company Limited in 198...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Vivek Dhawan
CEO, Head of ESG38.5yrsNessun dato6.66%
THB 2.2b
Thomas Abraham
CFO, Head Coach & Executive Director28.5yrsNessun dato0.76%
THB 251.7m
Deepak Panjwani
Chief Risk & Compliance Officerno dataNessun datoNessun dato
Paramjit Sawhney
President of International & Head Coachno dataNessun dato1.5%
THB 494.0m
Girish Wadhwa
President of Myanmar & Head Coachno dataNessun datoNessun dato
Duangnapa Tongsiri
President of Mega We Care Thailand & Head Coachno dataNessun dato1.48%
THB 486.3m
Sujintana Boonworapat
Corporate Secretaryno dataNessun datoNessun dato
Manoj Gurbuxani
Deputy Chief Financial Officer6.5yrsNessun dato0.000010%
THB 3.3k
Francis Rego
Regional Finance Head at Mega LifeSciences Pty. Ltd.no dataNessun datoNessun dato
28.5yrs
Durata media
59.5yo
Età media

Gestione esperta: Il team dirigenziale di MEGA è esperto e expertise (durata media dell'incarico 28.5 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Vivek Dhawan
CEO, Head of ESG13.5yrsNessun dato6.66%
THB 2.2b
Thomas Abraham
CFO, Head Coach & Executive Director28.5yrsNessun dato0.76%
THB 251.7m
Yim Chi
Independent Chairman13.4yrs฿1.65mNessun dato
Kirit Kumar Shah
Non-Executive Director13.4yrs฿694.58k49.81%
THB 16.4b
Shiraz Poonevala
Non-Executive Director13.4yrs฿694.58kNessun dato
Ishaan Shah
Non-Executive Director13.4yrs฿694.58k0.32%
THB 105.2m
Mechai Viravaidya
Chairman Emeritusless than a year฿2.32mNessun dato
Sameera Shah
Non-Executive Director13.4yrs฿694.58kNessun dato
Plakorn Wanglee
Independent Directorless than a yearNessun datoNessun dato
Vijay Karwal
Independent Director5.2yrs฿1.20mNessun dato
Nithinart Sinthudeacha
Independent Vice Chairman3.3yrs฿1.20mNessun dato
Ramachandran Rajamanickam
Independent Directorless than a yearNessun datoNessun dato
13.4yrs
Durata media
61.5yo
Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di MEGA è composto da personale esperto e esperto (durata media dell'incarico 13.4 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/07/31 16:26
Prezzo dell'azione a fine giornata2026/07/31 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Mega Lifesciences Public Company Limited è coperta da 15 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Thanapol JiratanakijCGS International
Chanpen SirithanarattanakulDBS Bank Ltd
Nantika WiangphoemDBS Bank Ltd